Bu sayfanın çevirisi deneyseldir ve geliştirilme aşamasındadır. imlerinizi bekliyoruz!

BeiGene Bilanço Sağlığı

Finansal Sağlık kriter kontrolleri 4/6

BeiGene şirketinin toplam hissedar öz sermayesi $3.4B ve toplam borcu $1.0B olup, bu da borç-öz sermaye oranını 30.8% seviyesine getiriyor. Toplam varlıkları ve toplam yükümlülükleri sırasıyla $5.7B ve $2.3B dir.

Anahtar bilgiler

30.8%

Borç/özkaynak oranı

US$1.04b

Borç

Faiz karşılama oranı	n/a
Nakit	US$2.59b
Eşitlik	US$3.37b
Toplam yükümlülükler	US$2.35b
Toplam varlıklar	US$5.71b

Son finansal sağlık güncellemeleri

Recent updates

BeiGene: Poised For Re-Rating As BTKi Sales Show Strong Beat

Aug 22

Analysts Just Made An Incredible Upgrade To Their BeiGene, Ltd. (NASDAQ:BGNE) Forecasts

Aug 14

BeiGene, Ltd. (NASDAQ:BGNE) Shares Fly 27% But Investors Aren't Buying For Growth

Aug 09

BeiGene: Navigating Patent Disputes Towards Profitability (Rating Upgrade)

Jun 21

We Think Some Shareholders May Hesitate To Increase BeiGene, Ltd.'s (NASDAQ:BGNE) CEO Compensation

May 30

Is BeiGene (NASDAQ:BGNE) Using Too Much Debt?

Apr 21

BeiGene Still Bleeding Red Ink Despite Blockbuster Drug

Mar 08

BeiGene, Ltd.'s (NASDAQ:BGNE) Intrinsic Value Is Potentially 26% Above Its Share Price

Jan 31

Here's Why BeiGene (NASDAQ:BGNE) Can Manage Its Debt Despite Losing Money

Oct 16

Is There An Opportunity With BeiGene, Ltd.'s (NASDAQ:BGNE) 39% Undervaluation?

Jul 11

Rock star Growth Puts BeiGene (NASDAQ:BGNE) In A Position To Use Debt

Jun 19

Revenues Not Telling The Story For BeiGene, Ltd. (NASDAQ:BGNE)

Apr 17

A Look At The Fair Value Of BeiGene, Ltd. (NASDAQ:BGNE)

Mar 24

Finansal Durum Analizi

Kısa Vadeli Yükümlülükler: BGNE 'nin kısa vadeli varlıkları ( $3.8B ) kısa vadeli yükümlülüklerini ( $1.9B ) aşıyor.

Uzun Vadeli Yükümlülükler: BGNE şirketinin kısa vadeli varlıkları ( $3.8B ) uzun vadeli yükümlülüklerini ( $407.2M ) aşmaktadır.

Borç-Özkaynak Tarihçesi ve Analizi

Borç Seviyesi: BGNE şirketinin toplam borcundan daha fazla nakiti var.

Borcun Azaltılması: BGNE şirketinin borç/öz sermaye oranı son 5 yılda 15.8% seviyesinden 30.8% seviyesine yükseldi.

Bilanço

Nakit Pist Analizi

Geçmişte ortalama olarak zarar eden şirketler için, en az 1 yıllık nakit akışına sahip olup olmadıklarını değerlendiriyoruz.

İstikrarlı Nakit Pisti: BGNE şirketinin mevcut serbest nakit akışına göre bir yıldan fazla yetecek nakit pisti bulunmaktadır.

Tahmini Nakit Akışı: BGNE tarihsel oranlara göre serbest nakit akışı büyümeye veya küçülmeye devam ederse yeterli nakit pistine sahip olup olmadığını belirlemek için yeterli veri yok.

BeiGene Bilanço Sağlığı

Finansal Sağlık kriter kontrolleri 4/6

Anahtar bilgiler

Son finansal sağlık güncellemeleri

Is BeiGene (NASDAQ:BGNE) Using Too Much Debt?

Here's Why BeiGene (NASDAQ:BGNE) Can Manage Its Debt Despite Losing Money

Rock star Growth Puts BeiGene (NASDAQ:BGNE) In A Position To Use Debt

Recent updates

BeiGene, Ltd. to Report Q3, 2024 Results on Nov 13, 2024

Global Head of R&D notifies of intention to sell stock

BeiGene, Ltd. Appoints Shalini Sharp to Board of Directors and Member of the Audit Committee, Effective September 27, 2024

President & COO notifies of intention to sell stock

BeiGene Receives Israeli Ministry of Health Approval for TEVIMBRA® for the Treatment of Oesophageal Squamous Cell Carcinoma (OSCC) After Prior Chemotherapy

President & COO notifies of intention to sell stock

BeiGene: Poised For Re-Rating As BTKi Sales Show Strong Beat

Analysts Just Made An Incredible Upgrade To Their BeiGene, Ltd. (NASDAQ:BGNE) Forecasts

Consensus estimates of losses per share improve by 31%

BeiGene, Ltd. (NASDAQ:BGNE) Shares Fly 27% But Investors Aren't Buying For Growth

Second quarter 2024 earnings: EPS and revenues exceed analyst expectations

BeiGene, Ltd. to Report Q2, 2024 Results on Aug 07, 2024

Beigene, Ltd. Appoints Aaron Rosenberg as the Principal Financial Officer, Effective from July 22, 2024

BeiGene, Ltd. Announces CFO Changes

BeiGene, Ltd. to Report First Half, 2024 Results on Aug 30, 2024

BeiGene: Navigating Patent Disputes Towards Profitability (Rating Upgrade)

BeiGene to Present New Data from SEQUOIA Study Evaluating BRUKINSA® plus Venetoclax in High-Risk First-Line CLL/SLL at EHA2024

We Think Some Shareholders May Hesitate To Increase BeiGene, Ltd.'s (NASDAQ:BGNE) CEO Compensation

BeiGene, Ltd. Announces New Analyses for BRUKINSA® (zanubrutinib) At ASCO Underscore Differentiated Clinical Profile for Treatment of CLL and SLL

BeiGene Highlights New Hematology Portfolio and Pipeline Data at EHA2024

First quarter 2024 earnings released: US$2.41 loss per share (vs US$3.35 loss in 1Q 2023)

BeiGene, Ltd. Receives European Commission Approval for Tislelizumab as Treatment for Non-Small Cell Lung Cancer

Is BeiGene (NASDAQ:BGNE) Using Too Much Debt?

BeiGene, Ltd., Annual General Meeting, Jun 05, 2024

Co-Founder recently sold US$7.5m worth of stock

Co-Founder notifies of intention to sell stock

BeiGene, Ltd. to Report Q1, 2024 Results on May 11, 2024

BeiGene, Ltd. Receives FDA Approval for TEVIMBRA for Treatment of Advanced or Metastatic Esophageal Squamous Cell Carcinoma After Prior Chemotherapy

Co-Founder notifies of intention to sell stock

BeiGene Still Bleeding Red Ink Despite Blockbuster Drug

BeiGene, Ltd. Announces FDA Accelerated Approval of BRUKINSA for the Treatment of Relapsed or Refractory Follicular Lymphoma

BeiGene, Ltd. to Present Clinical and Preclinical Data from Broad Portfolio and Pipeline at AACR Annual Meeting 2024

BeiGene, Ltd. Receives Positive CHMP Opinion for Tislelizumab as Treatment for Non-Small Cell Lung Cancer

Full year 2023 earnings released: US$8.45 loss per share (vs US$19.43 loss in FY 2022)

BeiGene, Ltd. Announces Adults Living with Chronic Lymphocytic Leukemia in Ontario and Quebec Now Have Access, Through Public Reimbursement, to BRUKINSA® (Zanubrutinib)

BeiGene, Ltd.'s (NASDAQ:BGNE) Intrinsic Value Is Potentially 26% Above Its Share Price

Now 21% undervalued after recent price drop

Beigene, Ltd. Announces Board Changes

Now 22% undervalued after recent price drop

Forecast to breakeven in 2026

BeiGene, Ltd. Announces FDA Approves Label Update for BRUKINSA (zanubrutinib) in Chronic Lymphocytic Leukemia

BeiGene, Ltd. Receives European Commission Approval for BRUKINSA®? (zanubrutinib) for the Treatment of Relapsed or Refractory Follicular Lymphoma

Co-Founder notifies of intention to sell stock

Third quarter 2023 earnings: EPS and revenues exceed analyst expectations

Consensus revenue estimates increase by 11%

Consensus EPS estimates upgraded to US$11.07 loss

Beigene, Ltd. Receives Positive Recommendation from Nice in U.K. for Adult Patients with Chronic Lymphocytic Leukemia

BeiGene, Ltd. Presentations at ESMO 2023 Demonstrate Robust Clinical Strategy for Tislelizumab as Monotherapy and in Combination with Pipeli

Here's Why BeiGene (NASDAQ:BGNE) Can Manage Its Debt Despite Losing Money

BeiGene Receives Positive CHMP Opinion for BRUKINSA®? (zanubrutinib) in Relapsed or Refractory Follicular Lymphoma

Consensus EPS estimates fall by 18%

BeiGene Receives Positive CHMP Opinion for BRUKINSA®? (zanubrutinib) in Relapsed or Refractory Follicular Lymphoma

U.S. FDA Accepts Biologics License Application in First-Line Advanced ESCC

BeiGene, Ltd. Announces Positive Regulatory Updates in Europe and the U.S. After Recently Regaining Global Rights for TEVIMBRA(R)

Beigene, Ltd. Announces Change of Chair of Audit Committee

New minor risk - Profitability

New minor risk - Shareholder dilution

New minor risk - Shareholder dilution

New minor risk - Shareholder dilution

New minor risk - Shareholder dilution

Second quarter 2023 earnings released: US$3.64 loss per share (vs US$5.51 loss in 2Q 2022)

Beigene Announces Positive CHMP Opinion for Tislelizumab as Treatment for Advanced or Metastatic ESCC

Beigene, Ltd. Announces FDA Acceptance of sNDA for Fifth Brukinsa(R) Indication

Is There An Opportunity With BeiGene, Ltd.'s (NASDAQ:BGNE) 39% Undervaluation?

BeiGene, Ltd. to Report First Half, 2023 Results on Aug 30, 2023

New minor risk - Shareholder dilution

Rock star Growth Puts BeiGene (NASDAQ:BGNE) In A Position To Use Debt

BeiGene Highlights Significant Brukinsa® (Zanubrutinib) Data at 17th International Conference on Malignant Lymphoma

Pharmacyclics LLC Files Complaint Against Beigene, Ltd. and Beigene USA, Inc

Now 20% undervalued after recent price drop

BeiGene Highlights Promising Data from Blood Cancer Portfolio and Pipeline at the European Hematology Association Hybrid Congress

BeiGene, Ltd. Announces Approval of BRUKINSA (Zanubrutinib) by Health Canada for the Treatment of Adult Patients with Chronic Lymphocytic Leukemia